Director Study Start Up United States
alnylam
About this role
Alnylam Pharmaceuticals is seeking a Director of Study Start-up to provide strategic and operational leadership for the study start-up portfolio across global clinical trials. The role involves overseeing end-to-end activities, improving processes, managing teams, and ensuring regulatory compliance to deliver high-quality outcomes.
Skills
Qualifications
About alnylam
alnylam.comNew Relic is a SaaS observability and telemetry platform that helps engineering teams instrument, monitor, and troubleshoot applications and cloud infrastructure. It ingests metrics, events, logs, traces, and browser real-user data to deliver APM, distributed tracing, infrastructure monitoring, log management, synthetics, and RUM. The platform provides unified dashboards, alerting, anomaly detection, and root-cause analysis, plus integrations with cloud providers, services, and CI/CD tooling. Teams use New Relic to improve performance, accelerate incident response, and gain end-to-end visibility into customer experience and system health.
About alnylam
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Leadership Team
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
Unlock Company Insights
View leadership team, funding history,
and employee contacts for alnylam.
Salary
$197k – $266k
per year